Nakajima et al. reported that 30 and 300 mg/kg edaravone reduced the levels of radiation-induced oral mucositis, myeloperoxidase activity, and apoptosis rate after comparing the results of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end label staining results with the control group [15]. This evidence concerns the gene MPO and oral mucositis.